Samsung Bioepis Co., Ltd. has received formal European Commission approval and marketing authorization for its Aybintio (bevacizumab) biosimilar. The nod follows an endorsement by the European Medicines Agency’s Committee for Medicinal Products for Human Use in June. Also see "Samsung Bioepis Bevacizumab Nod Sets Stage For EU Throwdown" - Generics Bulletin, 26 June, 2020.
The oncology biosimilar is the company’s fifth biosimilar approved for use in Europe following Benepali (etanercept), Flixabi (infliximab), Ontruzant (trastuzumab) and Imraldi (adalimumab)